Moreover, it has been demonstrated that the PD-L1/PD-1 pathway inhibits the anti-tumor immune response of T cells [13] and that PD-L1 preferentially modulates the secretion of regulatory cytokines in the tumor microenvironment [53]. The gene discussed is PDCD1; the disease is neoplasm.